PMID- 22663991
OWN - NLM
STAT- MEDLINE
DCOM- 20120920
LR  - 20120605
IS  - 1873-2623 (Electronic)
IS  - 0041-1345 (Linking)
VI  - 44
IP  - 5
DP  - 2012 Jun
TI  - Role of human leukocyte antigen, donor-specific antibodies, and their impact in 
      renal transplantation.
PG  - 1231-5
LID - 10.1016/j.transproceed.2011.10.054 [doi]
AB  - INTRODUCTION: The clinical significance of the presence of antibody against human 
      leukocyte antigen (HLAb) and donor-specific antibodies (DSAb) prior to renal 
      transplantation remains unclear. This study was done to assess the impact of HLAb 
      and DSAb on graft function, rejection episodes, and graft survival in renal 
      transplantation. METHODS: The Luminex (Luminex, Austin, Texas, United States) is 
      a solid-phase assay using micro-spheres and it is more sensitive at detecting 
      human leukocyte antigen (HLA) antibodies than conventional tests. This 
      retrospective analysis involved 141 consecutive renal transplant recipients 
      between May 2007 and 2009 and with a minimum of 2 years of follow-up. RESULTS: 
      Luminex was positive for HLA class I in 35 and negative in 106; similarly class 
      II positivity was noted in 23 and negative in 118. The DSAb were positive in 33 
      and negative in 108 recipients. The HLA class I, class II, and DSA-positive 
      groups showed no difference in renal function assessed by estimated glomerular 
      filtration rate (eGFR) at 2 years (52 +/- 29 vs 52 +/- 22; 56 +/- 29 vs 51 +/- 29; 48 +/- 
      18 vs 53 +/- 19; P = not significant [NS]). But rejection episodes at 1 year were 
      significantly high in HLA class I and DSAb-positive group (17/35 vs 27/106; P = 
      .019 and 16/33 vs 29/108; P = .035). The rejection episodes in the HLA class 
      II-positive group did not show any difference when compared with the negative 
      group (9/23 vs 40/118; P = .63). Graft survival was not affected by positivity to 
      any of these antibodies at 2 years. CONCLUSION: Having HLA class I, class II, and 
      DSAb does not have any influence on early and intermediate graft function. The 
      HLA class I and DSAb positivity increases rejection episodes within 1 year in 
      renal transplantation. Graft survival was not affected by class I, class II, and 
      DSAb at 2 years.
CI  - Crown Copyright (c) 2012. Published by Elsevier Inc. All rights reserved.
FAU - Thiyagarajan, U Mathuram
AU  - Thiyagarajan UM
AD  - Department of Infection, Immunity & Inflammation, Transplant Surgery Group, 
      University Hospitals of Leicester, Leicester General Hospital, Leicester, United 
      Kingdom.
FAU - Bagul, A
AU  - Bagul A
FAU - Frost, J
AU  - Frost J
FAU - Horsburgh, T
AU  - Horsburgh T
FAU - Nicholson, M L
AU  - Nicholson ML
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Transplant Proc
JT  - Transplantation proceedings
JID - 0243532
RN  - 0 (HLA Antigens)
RN  - 0 (Immunosuppressive Agents)
RN  - 0 (Isoantibodies)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - England
MH  - Female
MH  - Glomerular Filtration Rate
MH  - Graft Rejection/immunology/prevention & control
MH  - Graft Survival
MH  - HLA Antigens/*immunology
MH  - *Histocompatibility
MH  - Histocompatibility Testing
MH  - Humans
MH  - Immunosuppressive Agents/therapeutic use
MH  - Isoantibodies/*blood
MH  - Kidney Transplantation/adverse effects/*immunology
MH  - Male
MH  - Middle Aged
MH  - Retrospective Studies
MH  - Risk Assessment
MH  - Risk Factors
MH  - Time Factors
MH  - Treatment Outcome
MH  - Young Adult
EDAT- 2012/06/06 06:00
MHDA- 2012/09/21 06:00
CRDT- 2012/06/06 06:00
PHST- 2011/10/07 00:00 [received]
PHST- 2011/10/27 00:00 [accepted]
PHST- 2012/06/06 06:00 [entrez]
PHST- 2012/06/06 06:00 [pubmed]
PHST- 2012/09/21 06:00 [medline]
AID - S0041-1345(12)00318-1 [pii]
AID - 10.1016/j.transproceed.2011.10.054 [doi]
PST - ppublish
SO  - Transplant Proc. 2012 Jun;44(5):1231-5. doi: 10.1016/j.transproceed.2011.10.054.